ADIL · Adial Pharmaceuticals Inc Common Stock
View on chartInsiders & Stakes
| William B. Stilley III Chief Executive Officer | ▲ Buy | Grant | 1,261,779 Shares held | 5/23/2023 | View profile |
| Coastlands Capital LP 10% Owner | ▲ Buy | Open Market | 388,308 Shares held | 7/16/2026 | View profile |
| Matt Davidson Chief Development Officer | ▲ Buy | Grant | 297,491 Shares held | 6/12/2026 | View profile |
| Joseph Truluck Chief Financial Officer | ▲ Buy | Grant | 265,139 Shares held | 5/23/2023 | View profile |
| Johnson Bankole A. Chief Medical Officer | ▼ Sell | Open Market | 148,246 Shares held | 10/4/2021 | View profile |
| Cary J. Claiborne Chief Executive Officer | ▲ Buy | Grant | 40,417 Shares held | 4/7/2026 | View profile |
| Newman James W. Jr. Director | ▲ Buy | Open Market | 34,644 Shares held | 12/30/2021 | View profile |
| Tony Goodman Chief Operating Officer | ▲ Buy | Grant | 26,523 Shares held | 4/7/2026 | View profile |
| Vinay Shah Chief Financial Officer | ▲ Buy | Grant | 17,325 Shares held | 4/7/2026 | View profile |
| Kevin Schuyler Director | ▲ Buy | Grant | 9,213 Shares held | 4/7/2026 | View profile |
| Robertson H. Gilliland Director | ▲ Buy | Grant | 9,185 Shares held | 4/7/2026 | View profile |
Transaction History
| Coastlands Capital LP | ▲ Buy | Open Market | 1,233 | $3K | 7/16/2026 |
| Coastlands Capital LP | ▲ Buy | Open Market | 2,000 | $5K | 7/14/2026 |
| Coastlands Capital LP | ▲ Buy | Open Market | 1,700 | $5K | 7/10/2026 |
| Coastlands Capital LP | ▲ Buy | Open Market | 10,053 | $28K | 7/9/2026 |
| Coastlands Capital LP | ▲ Buy | Open Market | 25,000 | $65K | 6/29/2026 |
| Matt Davidson | ▲ Buy | Grant | 232,417 | $0 | 6/12/2026 |
| Matt Davidson | ▲ Buy | Grant | 61,647 | — | 6/11/2026 |
| Matt Davidson | ▲ Buy | Grant | 3,427 | — | 6/11/2026 |
| Matt Davidson | ▲ Buy | Grant | 1,822 | — | 6/11/2026 |
| Matt Davidson | ▲ Buy | Grant | 101 | — | 6/11/2026 |
| Vinay Shah | ▲ Buy | Grant | 17,325 | $0 | 4/7/2026 |
| Robertson H. Gilliland | ▲ Buy | Grant | 9,185 | $0 | 4/7/2026 |
| Cary J. Claiborne | ▲ Buy | Grant | 37,985 | $0 | 4/7/2026 |
| Tony Goodman | ▲ Buy | Grant | 26,510 | $0 | 4/7/2026 |
| Kevin Schuyler | ▲ Buy | Grant | 9,185 | $0 | 4/7/2026 |
| Kevin Schuyler | ▲ Buy | Open Market | 700 | $2K | 9/29/2023 |
| William B. Stilley III | ▲ Buy | Grant | 240,800 | $0 | 5/23/2023 |
| Cary J. Claiborne | ▲ Buy | Grant | 420,000 | $0 | 5/23/2023 |
| Joseph Truluck | ▲ Buy | Grant | 157,500 | $0 | 5/23/2023 |
| William B. Stilley III | ▼ Sell | Other | 166,667 | $0 | 12/30/2022 |
| Cary J. Claiborne | ▲ Buy | Grant | 75,000 | $32K | 9/20/2022 |
| Cary J. Claiborne | ▲ Buy | Grant | 25,000 | $11K | 9/19/2022 |
| Cary J. Claiborne | ▲ Buy | Grant | 1,000,000 | $0 | 8/18/2022 |
| William B. Stilley III | ▲ Buy | Grant | 250,000 | $0 | 2/23/2022 |
| Newman James W. Jr. | ▲ Buy | Open Market | 10,000 | $27K | 12/30/2021 |
| Newman James W. Jr. | ▲ Buy | Open Market | 5,000 | $14K | 12/30/2021 |
| Newman James W. Jr. | ▲ Buy | Open Market | 10,000 | $27K | 12/30/2021 |
| Kevin Schuyler | ▼ Sell | Gift | 312,990 | $0 | 12/23/2021 |
| William B. Stilley III | ▲ Buy | Open Market | 10,600 | $29K | 11/30/2021 |
| William B. Stilley III | ▲ Buy | Open Market | 10,000 | $26K | 11/29/2021 |
| Newman James W. Jr. | ▲ Buy | Open Market | 10,000 | $29K | 11/26/2021 |
| Johnson Bankole A. | ▼ Sell | Open Market | 200,000 | — | 10/4/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Adial Pharmaceuticals Announces Nasdaq Inducement Grant
Adial Pharmaceuticals disclosed a new inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is relevant as it relates to the company's adherence to exchange listing requirements. The stock currently trades well below its 52-week high, with recent volume spikes observed alongside the announcement.
Adial Pharmaceuticals Announces Nasdaq Inducement Grant. Adial Pharmaceuticals disclosed a new inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is relevant as it relates to the company's adherence to exchange listing requirements. The stock currently trades well below its 52-week high, with recent volume spikes observed alongside the announcement.